This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Supplement To Earnings News Release - 2Q2014

A reconciliation of GAAP to non-GAAP net income and EPS is provided in the tables that follow. Year-to-date results can be found in the attached tables.

Second Quarter   Second Quarter
$ in millions, except EPS amounts 2014   2013
GAAP EPS   $0.68   $0.30

Difference 3
  0.17   0.54
Non-GAAP EPS that excludes items listed below 1   $0.85   $0.84
Net Income        
GAAP net income 2   $2,004   $906
Difference   489   1,624
Non-GAAP net income that excludes items listed below 1,2   $2,493   $2,530
Decrease (Increase) in Net Income Due to Excluded Items:        

Acquisition- and divestiture-related costs 4
  $1,756   $1,768
Restructuring costs   421   278
Gain on AstraZeneca option exercise   (741)   --
Other   --   (13)
Net decrease (increase) in income before taxes   1,436   2,033

Income tax (benefit) expense 5
  (947)   (409)
Decrease (increase) in net income   $489   $1,624

“We delivered a strong first half of the year, making progress in transforming our operating model, fueling innovation and managing costs, while focusing on our best opportunities,” said Kenneth C. Frazier, chairman and chief executive officer, Merck. “I’m excited as we are preparing for a series of important and promising product launches later this year that we believe will make a meaningful difference to patients, healthcare providers and payers, while creating value for society and shareholders.”

2 of 13

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $92.89 -0.38%
FB $118.52 0.60%
GOOG $706.33 0.70%
TSLA $211.61 0.04%
YHOO $36.89 -0.14%


Chart of I:DJI
DOW 17,625.75 -34.96 -0.20%
S&P 500 2,041.56 -9.07 -0.44%
NASDAQ 4,689.3940 -27.70 -0.59%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs